Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Equivalents data on record, last reported at $49.6 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 32.5% to $49.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $49.6 million, a 32.5% decrease, with the full-year FY2025 number at $139.2 million, up 146.45% from a year prior.
  • Cash & Equivalents reached $49.6 million in Q1 2026 per IKT's latest filing, down from $139.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for IKT hit a ceiling of $139.2 million in Q4 2025 and a floor of $913420.0 in Q3 2024.
  • A 5-year average of $32.5 million and a median of $14.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 94.09% in 2023, then surged 4089.72% in 2025.
  • Tracing IKT's Cash & Equivalents over 5 years: stood at $7.2 million in 2022, then grew by 27.5% to $9.2 million in 2023, then soared by 516.36% to $56.5 million in 2024, then surged by 146.45% to $139.2 million in 2025, then plummeted by 64.39% to $49.6 million in 2026.
  • Business Quant data shows Cash & Equivalents for IKT at $49.6 million in Q1 2026, $139.2 million in Q4 2025, and $38.3 million in Q3 2025.